表紙
市場調査レポート

Tekmira Pharmaceuticals Corp.:製品パイプライン分析

Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 199816
出版日 ページ情報 英文 71 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
Tekmira Pharmaceuticals Corp.:製品パイプライン分析 Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2015
出版日: 2015年06月17日 ページ情報: 英文 71 Pages
概要

Tekmira Pharmaceuticals Corp.は、癌などの疾患向けの医薬品やドラッグデリバリーシステムを開発、商品化するバイオ医薬品企業です。

当レポートでは、Tekmira Pharmaceuticals Corp.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Tekmira Pharmaceuticals Corp.の基本情報

Tekmira Pharmaceuticals Corp.の概要

  • 主要情報
  • 企業情報

Tekmira Pharmaceuticals Corp.:R&Dの概要

  • 主な治療範囲

Tekmira Pharmaceuticals Corp.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Tekmira Pharmaceuticals Corp.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Tekmira Pharmaceuticals Corp.:薬剤プロファイル

  • TKM-PLK1
  • TKM-100802
  • 癌向けのCSN5を阻害するRNAiオリゴヌクレオチド
  • RIV型糖原病向けNAiオリゴヌクレオチド
  • 高トリグリセリド血症向けRNAiオリゴヌクレオチド
  • 肝細胞癌向けのWEE1を阻害するRNAiオリゴヌクレオチド
  • C型肝炎向けRNAiオリゴヌクレオチド
  • TKM-100701
  • TKM-ALDH2
  • TKM-HBV
  • TKM-Marburg

Tekmira Pharmaceuticals Corp.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Tekmira Pharmaceuticals Corp.:最近のパイプライン動向

Tekmira Pharmaceuticals Corp.:休止中のプロジェクト

Tekmira Pharmaceuticals Corp.:企業発表

Tekmira Pharmaceuticals Corp.:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07175CDB

Summary

Global Markets Direct's, 'Tekmira Pharmaceuticals Corp. - Product Pipeline Review - 2015', provides an overview of the Tekmira Pharmaceuticals Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Tekmira Pharmaceuticals Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Tekmira Pharmaceuticals Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Tekmira Pharmaceuticals Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Tekmira Pharmaceuticals Corp.'s pipeline products

Reasons to buy

  • Evaluate Tekmira Pharmaceuticals Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Tekmira Pharmaceuticals Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Tekmira Pharmaceuticals Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Tekmira Pharmaceuticals Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tekmira Pharmaceuticals Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Tekmira Pharmaceuticals Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Tekmira Pharmaceuticals Corp. Snapshot
    • Tekmira Pharmaceuticals Corp. Overview
    • Key Information
    • Key Facts
  • Tekmira Pharmaceuticals Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • Tekmira Pharmaceuticals Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Tekmira Pharmaceuticals Corp. - Pipeline Products Glance
    • Tekmira Pharmaceuticals Corp. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Tekmira Pharmaceuticals Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Tekmira Pharmaceuticals Corp. - Drug Profiles
    • TKM-Ebola-Guinea
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TKM-PLK1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TKM-100802
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TKMHBV-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TKMHBV-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCC-0346
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCC-0975
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CYT-003-QbG10
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit HBsAg for Hepatitis B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVP-018
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide to Inhibit CSN5 for Hepatocellular Carcinoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide to Inhibit WEE1 for Hepatocellular Carcinoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TKM-ALDH2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TKM-GSD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TKM-HTG
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TKM-Marburg
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TKMApoC-3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DVR-23
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Dengue
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Hepatitis B Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize Sting Receptor for Hepatitis B
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Tekmira Pharmaceuticals Corp. - Pipeline Analysis
    • Tekmira Pharmaceuticals Corp. - Pipeline Products by Target
    • Tekmira Pharmaceuticals Corp. - Pipeline Products by Route of Administration
    • Tekmira Pharmaceuticals Corp. - Pipeline Products by Molecule Type
    • Tekmira Pharmaceuticals Corp. - Pipeline Products by Mechanism of Action
  • Tekmira Pharmaceuticals Corp. - Recent Pipeline Updates
  • Tekmira Pharmaceuticals Corp. - Dormant Projects
  • Tekmira Pharmaceuticals Corp. - Company Statement
  • Tekmira Pharmaceuticals Corp. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Tekmira Pharmaceuticals Corp., Key Information
  • Tekmira Pharmaceuticals Corp., Key Facts
  • Tekmira Pharmaceuticals Corp. - Pipeline by Indication, 2015
  • Tekmira Pharmaceuticals Corp. - Pipeline by Stage of Development, 2015
  • Tekmira Pharmaceuticals Corp. - Monotherapy Products in Pipeline, 2015
  • Tekmira Pharmaceuticals Corp. - Partnered Products in Pipeline, 2015
  • Tekmira Pharmaceuticals Corp. - Partnered Products/ Combination Treatment Modalities, 2015
  • Tekmira Pharmaceuticals Corp. - Out-Licensed Products in Pipeline, 2015
  • Tekmira Pharmaceuticals Corp. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Tekmira Pharmaceuticals Corp. - Phase II, 2015
  • Tekmira Pharmaceuticals Corp. - Phase I, 2015
  • Tekmira Pharmaceuticals Corp. - Preclinical, 2015
  • Tekmira Pharmaceuticals Corp. - Discovery, 2015
  • Tekmira Pharmaceuticals Corp. - Pipeline by Target, 2015
  • Tekmira Pharmaceuticals Corp. - Pipeline by Route of Administration, 2015
  • Tekmira Pharmaceuticals Corp. - Pipeline by Molecule Type, 2015
  • Tekmira Pharmaceuticals Corp. - Pipeline Products by Mechanism of Action, 2015
  • Tekmira Pharmaceuticals Corp. - Recent Pipeline Updates, 2015
  • Tekmira Pharmaceuticals Corp. - Dormant Developmental Projects,2015
  • Tekmira Pharmaceuticals Corp., Subsidiaries

List of Figures

  • Tekmira Pharmaceuticals Corp. - Pipeline by Top 10 Indication, 2015
  • Tekmira Pharmaceuticals Corp. - Pipeline by Stage of Development, 2015
  • Tekmira Pharmaceuticals Corp. - Monotherapy Products in Pipeline, 2015
  • Tekmira Pharmaceuticals Corp. - Partnered Products in Pipeline, 2015
  • Tekmira Pharmaceuticals Corp. - Out-Licensed Products in Pipeline, 2015
  • Tekmira Pharmaceuticals Corp. - Pipeline by Top 10 Target, 2015
  • Tekmira Pharmaceuticals Corp. - Pipeline by Top 10 Route of Administration, 2015
  • Tekmira Pharmaceuticals Corp. - Pipeline by Top 10 Molecule Type, 2015
  • Tekmira Pharmaceuticals Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top